Biomarkers are measurable indicators of particular diseases or physiological processes. They are widely studied throughout all stages of drug development to determine the presence and/or remission of a disease. At Ncardia we generate iPSC-derived healthy or diseased models that express the biomarkers of interest and develop accurate biomarker detection assays to provide valuable insights on compound safety and efficacy.
- Precise treatment response
- Multiplexing options
- Customization available to fit your needs
Do you want to explore how this assay can help you progress your drug discovery programs? Contact our expert
Biomarkers used in the clinic for diagnosis and disease prognosis can be displayed by our iPSC-derived in vitro models. This helps find efficacious treatments based on clinically relevant readouts and detect unsafe drugs as early as possible. Our scientists develop and execute a number of customized sensitive assays for the detection of biomarkers:
- Homogeneous Time Resolved Fluorescence (HTRF)
- High content imaging
- Western Blot
Multiparametric functional and structural cardiac safety analysis with Ncardia’s human iPSC-derived cardiomyocytes
Cardiac troponin is a known biomarker that is released into circulation after cardiomyocyte structural damage. Many new therapeutic candidates are withdrawn because they induce this type of damage in the heart. In this example, our team combined AlphaLISA with impedance analysis to assess Troponin I release, contractility and viability after treatment with known cardiotoxic compounds.
High-throughput screening of anti-hypertrophy drugs based on NT-proBNP biomarker detection using high content imaging
To identify new treatments for cardiac hypertrophy, our scientists generated an iPSC-derived model of hypertrophic cardiomyopathy and used high content imaging in a secondary screening of 341 compounds for hit validation. The intracellular expression of NT-proBNP, biomarker of cardiac hypertrophy, was used as readout to study the anti-hypertrophic compound effect.
Analysis of neuroinflammatory biomarkers in activated Ncyte Astrocytes with HTRF
HTRF assay can detect the activation of intracellular phospho-proteins and secreted proteins that modulate neuroinflammation, providing a platform to determine the efficacy of potential anti-inflammatory treatments for neurodegenerative diseases.
Our work centers on a simple yet powerful premise:
When we combine deep iPSC knowledge, broad assay capabilities and a demonstrated ability to integrate the biology of human diseases into preclinical research, we can help drug developers make critical decisions earlier and with more confidence.
Study compound-induced effects on blood vessel formationAssay
Evaluate and quantify the levels of clinically relevant biomarkersAssay
Obtain real-time recordings of intracellular calcium fluctuationsAssay
Study drug-induced effects on contractility of cardiac or skeletal muscle cellsAssay
Determine the electrophysiological effects of your therapeutic candidatesAssay
Evaluate endothelial permeability in short and long termAssay
Study drug-induced phenotypic changes in the cell model of your interestAssay
Obtain precise information on compounds' impact on metabolic processes